Calculators, Algorithms, Drug Interaction CheckersTools
Back To Search Results

Bisphosphonate Related Jaw Osteonecrosis

Author: Mohit Gupta Editor: Neha Gupta Updated: 7/24/2023 10:00:45 PM

Introduction

The widespread use of bisphosphonate (BP) to treat various medical conditions led to increased recognition of their possible association with osteonecrosis (ON) of the jaw.[1] Bisphosphonates are highly efficient antiresorptive drugs used to treat diseases with increased osteoclast activity such as cancer-related conditions, osteoporosis, multiple myeloma, Paget disease, osteosclerosis, and fibrous dysplasia.[2] Although rare, avascular osteonecrosis of the jaw has been recently recognized as a complication of bisphosphonate use. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is defined as a current or previous treatment with BPs that leads to an exposed bone or bone that can be probe through a fistula in the maxillofacial region that does not heal within eight weeks. The patient has no history of radiation therapy in the craniofacial region.[3][4] Eight weeks is considered because most surgical and infectious sites heal in this time frame, even if complications such as postsurgical infection, chemotherapy, or systemic diseases are present.

Etiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

Bisphosphonates inhibit bone resorption by causing osteoclast cell apoptosis, impairing the osteoclast’s resorptive capacity, and preventing osteoclast formation.[5] They have a high affinity for bone minerals and accumulate mainly in the sites of osteoclast activity.[5] Without resorption and new bone formation, old bone survives beyond its lifespan, and its capillary network is not maintained, leading to avascular necrosis of the jaw. Also, high potency biphosphonates can lead to necrosis by the toxicity of soft tissue and bone cells, further complicated by infection.[6] Due to altered wound healing, delayed epithelial closure of a mucosal opening in the mouth leads to chronic infection and the necrosis of bone.[7] Osteonecrosis develops in the jaw because this bone has a higher remodeling rate than other bones, making it more prone to the effect of bisphosphonates.

Epidemiology

Intravenous (IV) Versus Oral Biphosphonates

Osteonecrosis of the jaw is mainly reported with the use of more potent nitrogen-containing BPs like pamidronate and zoledronic acid. However, the incidence is higher with the latter - zoledronic acid causes a higher antiresorptive activity, leading to decreased bone turnover.[8]

Oral biphosphonates rarely cause osteonecrosis of the jaw. They are less aggressive than intravenous BP, and the osteonecrosis caused by oral BP responds better to treatment. Oral BPs are less liposoluble, limiting their intestinal absorption, resulting in a lower accumulation in the bone.[9]

Dose and Duration

The incidence of osteonecrotic events increases with a higher dose of potent BPs administered for a longer duration.[10][11][12][13][14] The risk ranges from greater than 1% at 12 months to 11% after four years of treatment - taking zoledronic acid alone increases the risk of osteonecrosis to 21% after the third year. Due to the slow accumulation of oral BPs, no clinically exposed bone appears until after 3-year treatment, and incidence and severity increase with each additional year of use.

Osteoporosis and Oncology Patients 

The frequency of biphosphonate-induced osteonecrosis in osteoporosis is very low, ranging from 0.15% to less than 0.001% person-years of exposure, and is only slightly higher than in non-osteoporotic patients. In oncology patients with bone metastasis, the risk is much higher as they are exposed to more intensive osteoclast inhibition and high-dose intravenous BPs. Also, the incidence varies according to the underlying condition. Wang et al. conducted a 5-year retrospective study of 292 patients treated with IV BPs that develop osteonecrosis. They found that 3% to 8% of patients had multiple myeloma, 2% to 5% breast cancer, and 2.9% prostate cancer.[15] Abu-Id et al.'s retrospective study found that osteonecrosis developed in 2 to 11% of multiple myeloma patients, 1% to 7% of breast cancer patients, and 6% to 15% of prostate cancer patients.[16]

Location

Osteonecrosis occurs most frequently in the mandible than the maxilla. It almost always begins in the alveolar bone due to its greater bone turnover rate, which relies on osteoclast-related remodeling due to occlusion and denture wearing pressure and tension forces.[17] The most common affected sites are nonhealing dentoalveolar sites, traumatized palatal and mandibular tori, and exposed portions of the mylohyoid ridge.

Incidence of BP-induced ON of the jaw increases with:

  1. More potent nitrogen-containing IV BPs
  2. High dosage and more prolonged duration
  3. Oncology patients with bone metastasis
  4. Areas with a high bone turnover rate like the alveolar bone of the mandible

Pathophysiology

Risk Factors

Several factors increase the risk of developing bisphosphonates-related osteonecrosis of the jaw:

1) Invasive oral procedures such as tooth extraction, periodontal surgery, and oral implant placement, and the use of dentures increase the rate of bone turnover and the risk of osteonecrosis.[18]

2) Comorbidities like cancer, chemotherapy, low hemoglobin levels, diabetes mellitus, renal dialysis, hypertension, hyperlipidemia, and hypercholesterolemia.[19]

3) Concomitant medications: corticosteroids and H2 blocking drugs, which increase BP absorption. Antiangiogenic agents, particularly sunitinib and bevacizumab. Erythropoietin and cyclophosphamide therapy.[20]

4) Infection: it is still unclear if osteonecrosis precedes or follows the infection. However, polymorphonuclear aggregates and bacterial microfilm in the surrounding tissue have been associated with bone resorption and necrosis.[21][22]

BPs inhibit the proliferation and viability of oral keratinocytes, damaging the oral mucosa integrity and increasing the risk of infection.[23][24][25] Also, BPs impair the immune response to infection by activating gamma, delta T-cells stimulating the production of pro-inflammatory cytokines and later depletion of T cells.

5) Genetic predisposition: polymorphism in farnesyl pyrophosphate synthase or CYP2C8 coding for a cytochrome P450 enzyme predisposes some individuals to bisphosphonate-associated osteonecrosis of the jaw in multiple myeloma.[26][27][28]

6) Other risk factors include increasing age, alcohol, and tobacco use.

Histopathology

Resected necrotic bone from BRONJ patients does not demonstrate any unique features of the disease.[29][30] The most frequently found microorganisms in the exposed bone sites are Actinomyces, Veillonella, Eikenella, and Moraxella species - penicillin-sensitive organisms. The presence of sulfur granules in deeper tissue and drainage areas supports the diagnosis of actinomycosis and requires appropriate treatment.[31]

History and Physical

Most cases of BRONJ occur after a dental intervention that affects bone, but osteonecrosis can also present spontaneously.[4] The necrotic bone may remain asymptomatic for a prolonged period or develop symptoms, mainly due to localized inflammation of soft tissue.[29]

Practitioners must consider BRONJ if patients with a history of anti-resorptive drug use present delayed healing after oral surgery, infection, and swelling in the surrounding soft tissue, numbness, paraesthesia, or bone exposure. But, clinicians should be aware that BRONJ lesions may also be an incidental discovery.

The altered nerve sensation described by some patients is due to compression of the neurovascular bundle causing paresthesia, or even anesthesia of the associated branch of the trigeminal nerve.[32][33] Hypoesthesia or anesthesia of the lower lip has been reported as an early symptom of BRONJ.

Complications of BRONJ include tissue ulceration, intra-and extraoral sinus tracts, and fistula.[34] Chronic maxillary sinusitis in patients with maxillary bone involvement and fracture in edentulous patients with oral implants have also been reported.[35]

Signs and Symptoms

  1. None/asymptomatic
  2. Pain
  3. Soft tissues infection with inflammation, ulceration, and suppuration
  4. Formation of intra-and extraoral sinus tracts and fistulas
  5. Paresthesia or anesthesia of an associated nerve
  6. Fracture
  7. Chronic maxillary sinusitis
  8. A radiographic appearance from no alterations to varying radiolucencies and radiopacities

Evaluation

Blood Test

It measures the C-terminal telopeptide (CTX) value, which depicts the level of octapeptide fragment released due to osteoclastic bone resorption from type I bone collagen.[36] Its levels are related to the number of osteonecrotic lesions, stage of disease, and bone turnover index.[37] A lower value represents a high-risk patient with suppressed bone turnover and reduced healing capacity. C-terminal telopeptide less than 100 pg/ml equals high risk, 100 to 150 pg/ml equals moderate risk, and greater than 150 pg/ml equals minimal or no risk.

Radiographic Appearance

Radiographically, BRONJ can range from no alterations to varying radiolucencies or radio-opacities. Osteolytic lesions may appear less or more radiodense, providing a similar radiographic appearance as metastatic bone. Altered bone morphology, periosteal bone formation, increased bone density, or sequestration may be radiographic findings of BRONJ. Early radiographic signs along alveolar bone may include widened periodontal ligament space and sclerosis of lamina dura.

Imaging Modalities and Diagnostic Tests

Due to the nonspecific radiographic features of the condition, imaging provides a good evaluation of the area involved and can assist in identifying the extent of bone and soft tissue disease but does not provide any definitive differentiation of osteonecrosis of the jaw from other conditions.[38]

Conventional radiographs

Intraoral and panoramic radiographs are easy to acquire, inexpensive, deliver low radiation, and provide a good view. They are helpful to assess early features: thickening of lamina dura, increased trabecular density, incomplete healing of extraction socket, widening of periodontal ligament space, sinus floor cortication, periosteal bone, and sequestrum formation. Poor quality images do not clearly demarcate between necrotic and healthy bone. Disease at early stages can be frequently missed. Despite limitations, they form the first line of routine radiological investigation.[39]

Cone beam CT scan

Cone beam CT scan provides tridimensional imaging of the involved cancellous and cortical bone and identifies osteosclerotic and osteolytic regions.[39] It can also evaluate sequestrum, periosteal bone reaction, and the integrity of the vital adjacent structures [40][41], potential fistula tract, cortical erosion, and incomplete extraction socket healing.[40][42][43][44][43]

The early stage of osteonecrosis may not be detected, but cortical and trabecular bone changes at the symptomatic site can aid in diagnosis. CBCT has similar findings of the osteonecrotic areas as the CT scan but imparts lower radiation and has higher spatial resolution with better image quality, particularly for the cancellous bone in a small field of view.[45][46] The major limitation is poor soft tissue details due to low contrast resolution.

MRI

MRI currently may be the method of choice to detect the early bone marrow and soft tissue changes surrounding the osteonecrotic area. Osseous change evaluation by MRI is similar to CT imaging. One consistent MRI findings are the decreased bone marrow signal intensity on T-1 weighted images resulting from progressive cell death and host response through repair, i.e., edema.[41][47][48][42] Irregular gadolinium enhancement around osteolytic lesions is observed. An MRI shows non-enhancement in regions of ischemia, especially in T-1 weighted sequences, low signal intensity in areas of fibrosis and sclerosis on T-1 and T-2 weighted images, and increased signal intensity along the unexposed diseased bone.[47][49] However, MRI may not demonstrate the full extent of bony changes and may give a false-positive diagnosis.

Nuclear Imaging with Bone Scintigraphy

Technetium-99 radioisotope scintigraphy has a high sensitivity for diagnosing early disease and ischemic osteonecrosis. Its sensitivity depends on the stage of osteonecrotic lesion and the change in vascularity.[39] It shows increased radionuclide uptake in surrounding areas with increased perfusion and blood pool, locating osteonecrotic regions more precisely.

The main drawbacks include significant radiation exposure, lengthy procedure, and low resolution, which sometimes make it challenging to differentiate between inflammatory and metastatic processes and heal osteolytic lesions and progressing osteoblastic lesions.

Combining CBCT with scintigraphy for diagnosing osteomyelitis [46] or using contrast agents with MRI, sequential imaging, and manipulating image planes can all be helpful measures to diagnose early or preclinical stages of BRONJ.

Treatment / Management

Treatment depends on age, gender, disease stage, lesion size, comorbidities, and medication. Still, since their influence on disease course and treatment response is unknown, clinical judgment guides the treatment approach. Other important factors are prognosis, life quality expectancy, and the patient's ability to cope with the disease.

No evidence-based guidelines for the treatment of BRONJ are currently available, but the treatment goal is to alleviate pain, control infection, and stabilize the progression of exposed bone.

Conservative Therapy

The mainstay of care is conservative therapy, and this may provide long-term symptomatic relief.[50][51](A1)

  1. Pain control and optimal oral hygiene, including diligent home care and regular dental visits.
  2. Managing infection and active dental disease: use of 0.12% chlorhexidine digluconate oral antimicrobial rinses and systemic antibiotic therapy.[52][53][54] Penicillin VK, 500 mg, four times daily is the antibiotic of choice. This formulation of penicillin is non-toxic and can be used long-term without superinfection and development of candidiasis. If long-term antibiotic usage is a concern, then it can be taken only during episodes of pain. If the patient is allergic to penicillin, then levofloxacin, 500 mg, once daily, is the best alternative. Other alternatives include doxycycline, 100 mg daily, or azithromycin, 250 mg daily. However, levofloxacin and azithromycin should be used for only 21 days or less due to their potential to raise liver enzymes. If this antibiotic protocol is ineffective, adding 500 mg of metronidazole three times daily for ten days is recommended.
  3. Teriparatide improves osseous wound healing in the oral cavity.[55] However, it is not recommended for patients at low risk of osteonecrosis of the jaw or fracture, but adding it to the treatment regimen of the osteoporotic patient with established osteonecrosis may benefit them.[56][57][58] The same approach is not recommended for a cancer patient or those who have received skeletal radiation or have active bone metastasis. These patients have a risk of development or advancement of bone malignancies.
  4. Reduce the contact of the oral prosthesis with the exposed bone.
  5. Repeat the C-terminal telopeptide test (CTX) after six months of drug holiday. Some cases resolve with CTX value rising above 150 pg/ml. Many show clinical and radiographic signs of improvement as separation of necrotic bone from healthy bone occurs, followed by sequestration and debridement. Most of the oral BRONJ cases are resolved by CTX guided protocol. Regular follow-ups must be done to keep the CTX value above 150 pg/ml using incremental drug schedules and alternative drugs.
    6. (A1)

Surgical Therapy 

Lack of symptomatic or radiographic improvement with various treatment modalities indicates permanent bone defect and need surgical intervention.

  1. The osteotomy of the affected area needs to be performed with resection margins extending into the adjacent healthy bone. Soft tissues should be closed with a tension-free closure and no underlying sharp edges that could lead to a mucosal breakdown.[59]
  2. Microvascular composite tissue grafting and reconstruction procedures should be considered in patients with pathological fractures, disease extending to the sinus or inferior border of the mandible, or if osteotomy leads to discontinuity defect.

Experimental Therapy

The various treatment approaches include the use of hyperbaric oxygen [60][61], bone marrow stem cell intralesional transplantation [62], local application of platelet-derived growth factor [63], low-level laser therapy [64][65], or using them in combination with conservative or surgical debridement, but their effect on the treatment outcome needs further substantiation.(A1)

The most recent recommendations advocate a non-surgical treatment approach due to impaired wound healing. Still, few studies included radical resection to viable bone and hermetic wound closure, with soft tissue being the only curative approach.[16] Combining various approaches like marginal resection and platelet-derived growth factors has been advocated by many studies.[66](B2)

Treatment Approach Review

  1. Conservative and supportive therapy for pain and infection control
  2. Surgical therapy for permanent bone defects and sequestration
  3. Experimental therapy consisting of hyperbaric oxygen, bone marrow stem cell intralesional transplantation, platelet-derived growth factor, low-level laser therapy.

Differential Diagnosis

The presence of exposed bone characterizes BRONJ. In the absence of exposed bone, BRONJ should be differentiated from the following:

  • Periodontal and periapical pathosis
  • Sinusitis
  • Gingivitis or mucositis
  • Temporomandibular disorders
  • Osteomyelitis
  • Metastatic bone tumors
  • Osteonecrosis induced by neuralgia
  • Osteoradionecrosis

Other conditions that may present with exposed bone but are not linked to bisphosphonate use include:

  • Cement osseous dysplasia with secondary sequestration
  • Trauma
  • Infectious osteomyelitis
  • Osteonecrosis following Herpes zoster infection
  • HIV-associated necrotizing ulcerative periodontitis

Staging

Very little evidence is reviewed for the staging of BRONJ. So staging recommendations should be considered as consensus statements. The current staging system is developed by Ruggiero and colleagues [67]  and is adopted by The American Association of Oral and Maxillofacial Surgeons (AAOMS).[68][69] The stage system is important to identify stage characteristics and provide appropriate diagnosis and management.

Stage 1 patients have exposed bone and are asymptomatic with no localized soft tissue infection. 

Stage 2 patients have exposed bone, pain, and regional soft tissue inflammation or infection.

Stage 3 patients have exposed bone with associated pain, localized soft tissue inflammation (or secondary infection), pathologic fracture, and extraoral or oral-antral fistula. Radiographically, the bone show osteolysis extending to the inferior mandibular border or maxillary sinus floor.

Recently, AAOMS added stage 0 to the staging system, referring to patients who take bisphosphonates and present with non-specific clinical findings and symptoms. Term stage 0 can lead to overdiagnosis that can have detrimental effects on the patient’s skeletal health if modification of anti-resorptive medication regimen is done as similar presenting symptoms may lead to a different diagnosis [70].

Deterrence and Patient Education

Prevention is the best approach and requires good communication among dentists, oral surgeons, physicians, nurse practitioners, and oncologists to develop measures to avoid the development of BRONJ.

Recommendations Before Initiating Bisphosphonate Therapy

Around 4 to 6 monthly doses are required to affect bone healing in jaws significantly; it is recommended to take preventive measures during this period.

  1. Perform prophylactic dental examination and maintenance of good oral hygiene and regular dental visits.
  2. Educate patients regarding home hygiene and self-maintenance.
  3. Educate patients regarding the risk of BRONJ with bisphosphonate therapy.
  4. Develop a dental treatment plan focused on correcting pathological conditions and stabilizing dentition to prevent the need for invasive procedures after the BP therapy is initiated.
  5. Extract unrestorable, abscessed, and periodontally compromised teeth.
  6. Restorative and prosthodontics procedures can be later accomplished, but dental implant placement and orthodontic treatment are not recommended. However, patients on BP for osteoporosis are currently not contraindicated for implant placement, but appropriate informed consent and documentation are recommended.

Recommendations for Patients Receiving BP Therapy

After 4 to 6 doses of BP, bone turnover is significantly suppressed, making bone healing unpredictable and risky for ON.

  1. Educate patients regarding the risk of BRONJ with bisphosphonate therapy.
  2. Educate patients regarding home hygiene and self-maintenance.
  3. Oral surgical procedures like extractions, bone contouring, grafting, periodontal, and apical surgeries should be avoided.[17]
  4. If possible, endodontic treatment is preferred over extractions and periapical surgery.
  5. Noninvasive restorative procedures like crowns, bridges, removable partial and complete dentures are recommended to prevent future surgical procedures.
  6. Orthodontic procedures are not recommended.
  7. Elective dentoalveolar surgical procedures like asymptomatic teeth extraction, implant placement, tori reduction are not recommended.
  8. Unrestorable teeth preferably should be treated with root canals and crown amputation; mobile teeth are best splinted, failed root canals should be retreated.
  9. If tooth extraction is unavoidable, the patient should be educated regarding the risk of developing BRONJ, and informed consent should be signed before the procedure.
  10. It is necessary to stratify the risk for patients on BP requiring extensive invasive oral surgery and patients with accompanying multiple risk factors like steroid treatment, immunodeficiency, or diabetes mellitus.
  11. Drug holiday: dental practitioners should not indicate discontinuing bisphosphonate drugs since there is no evidence that the risk of BRONJ reduces when stopping the medication before dental procedures because they stay in the bone for years.[71] 

Pearls and Other Issues

Besides the antiresorptive drugs, antiangiogenic drugs can also cause osteonecrosis of the jaw. That is why the condition is nowadays referred to as medication-related osteonecrosis of the jaw (MRONJ).

Enhancing Healthcare Team Outcomes

Prompt recognition of osteonecrosis by the interprofessional team is important for improving outcomes. Prescribing providers include primary care providers, dentists, orthopedists, rheumatologists, and oncologists. Pharmacists provided education to patients and their families, monitor compliance, and provide feedback to the team. Specialty care nurses, including infusion nurses, orthopedic nurses, and otolaryngology, provide education, monitor patients, and inform the team about status changes or issues. Good communication among the team, patient education, appropriate preventive measures, and treatment aimed at pain and infection control can enhance the patient care outcomes for patients on bisphosphonates who are at the risk of developing or having established osteonecrosis of the jaw. [Level 5]

Media


(Click Image to Enlarge)
Jaw Osteonecrosis
Jaw Osteonecrosis Image courtesy S Bhimji MD

References

[1]

Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D. Osteonecrosis of the jaw: more research needed. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2006 Oct:21(10):1503-5     [PubMed PMID: 16995804]

[2]

McClung MR. Bisphosphonates. Endocrinology and metabolism clinics of North America. 2003 Mar:32(1):253-71     [PubMed PMID: 12699302]

[3]

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E, American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2007 Oct:22(10):1479-91     [PubMed PMID: 17663640]

Level 3 (low-level) evidence

[4]

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2014 Oct:72(10):1938-56. doi: 10.1016/j.joms.2014.04.031. Epub 2014 May 5     [PubMed PMID: 25234529]

[5]

Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000 Jun 15:88(12 Suppl):2961-78     [PubMed PMID: 10898340]

Level 3 (low-level) evidence

[6]

Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007 Sep:41(3):318-20     [PubMed PMID: 17572168]

Level 3 (low-level) evidence

[7]

Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008 May:42(5):841-7. doi: 10.1016/j.bone.2008.01.003. Epub 2008 Jan 18     [PubMed PMID: 18314405]

[8]

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer journal (Sudbury, Mass.). 2001 Sep-Oct:7(5):377-87     [PubMed PMID: 11693896]

Level 1 (high-level) evidence

[9]

Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2007 Dec:65(12):2397-410     [PubMed PMID: 18022461]

[10]

Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. Journal of the American Dental Association (1939). 2008 Jan:139(1):23-30     [PubMed PMID: 18167381]

Level 2 (mid-level) evidence

[11]

Fellows JL, Rindal DB, Barasch A, Gullion CM, Rush W, Pihlstrom DJ, Richman J, DPBRN Collaborative Group. ONJ in two dental practice-based research network regions. Journal of dental research. 2011 Apr:90(4):433-8. doi: 10.1177/0022034510387795. Epub 2011 Feb 11     [PubMed PMID: 21317245]

Level 2 (mid-level) evidence

[12]

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. The New England journal of medicine. 2007 Nov 1:357(18):1799-809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17     [PubMed PMID: 17878149]

Level 1 (high-level) evidence

[13]

Powell D, Bowler C, Roberts T, Garton M, Matthews C, McCall I, Davie M. Incidence of serious side effects with intravenous bisphosphonate: a clinical audit. QJM : monthly journal of the Association of Physicians. 2012 Oct:105(10):965-71     [PubMed PMID: 22753670]

[14]

Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clinical drug investigation. 2013 Feb:33(2):117-22. doi: 10.1007/s40261-012-0041-1. Epub     [PubMed PMID: 23184667]

Level 2 (mid-level) evidence

[15]

Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2007 Jul:65(7):1328-31     [PubMed PMID: 17577497]

Level 2 (mid-level) evidence

[16]

Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, Russo PA, Kreusch T. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2008 Mar:36(2):95-103. doi: 10.1016/j.jcms.2007.06.008. Epub 2008 Jan 30     [PubMed PMID: 18234504]

Level 2 (mid-level) evidence

[17]

Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2005 Nov:63(11):1567-75     [PubMed PMID: 16243172]

[18]

Mellal A, Wiskott HW, Botsis J, Scherrer SS, Belser UC. Stimulating effect of implant loading on surrounding bone. Comparison of three numerical models and validation by in vivo data. Clinical oral implants research. 2004 Apr:15(2):239-48     [PubMed PMID: 15008937]

Level 3 (low-level) evidence

[19]

Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. The American journal of medicine. 2008 Jun:121(6):475-483.e3. doi: 10.1016/j.amjmed.2008.01.047. Epub     [PubMed PMID: 18501224]

Level 1 (high-level) evidence

[20]

Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Dec:18(12):2015-9     [PubMed PMID: 17804475]

Level 2 (mid-level) evidence

[21]

Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. Journal of the American Dental Association (1939). 2009 Oct:140(10):1259-65     [PubMed PMID: 19797556]

[22]

Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, Rizzoli R, Saffar JL, Samson J. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone. 2009 Nov:45(5):843-52. doi: 10.1016/j.bone.2009.07.011. Epub 2009 Jul 22     [PubMed PMID: 19631301]

[23]

Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. Journal of bone and mineral metabolism. 2009:27(6):663-72. doi: 10.1007/s00774-009-0090-6. Epub 2009 May 13     [PubMed PMID: 19436946]

Level 3 (low-level) evidence

[24]

Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, Kousteni S, Raghavan S. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Annals of the New York Academy of Sciences. 2011 Feb:1218():62-79. doi: 10.1111/j.1749-6632.2010.05835.x. Epub     [PubMed PMID: 21291478]

[25]

Ravosa MJ, Ning J, Liu Y, Stack MS. Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Archives of oral biology. 2011 May:56(5):491-8. doi: 10.1016/j.archoralbio.2010.11.003. Epub 2010 Dec 10     [PubMed PMID: 21146154]

[26]

Marini F, Tonelli P, Cavalli L, Cavalli T, Masi L, Falchetti A, Brandi ML. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Frontiers in bioscience (Elite edition). 2011 Jan 1:3(1):364-70     [PubMed PMID: 21196316]

Level 2 (mid-level) evidence

[27]

English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and clinical risk management. 2010 Nov 19:6():579-83. doi: 10.2147/TCRM.S14303. Epub 2010 Nov 19     [PubMed PMID: 21151627]

[28]

Sarasquete ME, García-Sanz R, Marín L, Alcoceba M, Chillón MC, Balanzategui A, Santamaria C, Rosiñol L, de la Rubia J, Hernandez MT, Garcia-Navarro I, Lahuerta JJ, González M, San Miguel JF. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008 Oct 1:112(7):2709-12. doi: 10.1182/blood-2008-04-147884. Epub 2008 Jul 1     [PubMed PMID: 18594024]

[29]

Allen MR, Ruggiero SL. Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2009 Jul:67(7):1373-7. doi: 10.1016/j.joms.2009.03.048. Epub     [PubMed PMID: 19531405]

Level 2 (mid-level) evidence

[30]

Allen MR, Pandya B, Ruggiero SL. Lack of correlation between duration of osteonecrosis of the jaw and sequestra tissue morphology: what it tells us about the condition and what it means for future studies. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2010 Nov:68(11):2730-4. doi: 10.1016/j.joms.2010.05.090. Epub     [PubMed PMID: 20869151]

[31]

Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral and maxillofacial surgery clinics of North America. 2007 Nov:19(4):487-98, v-vi     [PubMed PMID: 18088900]

[32]

Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop TS, Brinzaniuc K, Petcu EB, Miroiu RI. Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vascular cell. 2013 Jan 14:5(1):1. doi: 10.1186/2045-824X-5-1. Epub 2013 Jan 14     [PubMed PMID: 23316704]

[33]

Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, Arduino PG, Broccoletti R, Musciotto A, Di Fede O, Lazarovici TS, Campisi G, Yarom N. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. The American journal of medicine. 2010 Nov:123(11):1060-4. doi: 10.1016/j.amjmed.2010.04.033. Epub 2010 Sep 28     [PubMed PMID: 20851366]

Level 2 (mid-level) evidence

[34]

Otto S, Hafner S, Grötz KA. The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2009 Mar:67(3):589-92. doi: 10.1016/j.joms.2008.09.028. Epub     [PubMed PMID: 19231785]

[35]

Pogrel MA. Bisphosphonates and bone necrosis. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2004 Mar:62(3):391-2     [PubMed PMID: 15015179]

Level 3 (low-level) evidence

[36]

Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcified tissue international. 2000 Feb:66(2):100-3     [PubMed PMID: 10652955]

Level 1 (high-level) evidence

[37]

Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, Nakayama T, Bessho K. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. International journal of oral and maxillofacial surgery. 2012 Nov:41(11):1397-403. doi: 10.1016/j.ijom.2012.06.020. Epub 2012 Jul 26     [PubMed PMID: 22840716]

Level 2 (mid-level) evidence

[38]

Morag Y, Morag-Hezroni M, Jamadar DA, Ward BB, Jacobson JA, Zwetchkenbaum SR, Helman J. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. Radiographics : a review publication of the Radiological Society of North America, Inc. 2009 Nov:29(7):1971-84. doi: 10.1148/rg.297095050. Epub     [PubMed PMID: 19926757]

[39]

Store G, Larheim TA. Mandibular osteoradionecrosis: a comparison of computed tomography with panoramic radiography. Dento maxillo facial radiology. 1999 Sep:28(5):295-300     [PubMed PMID: 10490748]

Level 1 (high-level) evidence

[40]

Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2007 Aug:104(2):249-58     [PubMed PMID: 17560140]

[41]

Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clinical oral investigations. 2010 Jun:14(3):311-7. doi: 10.1007/s00784-009-0293-1. Epub 2009 Jun 10     [PubMed PMID: 19513765]

[42]

Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, Tregnaghi A, Pietrogrande F, Procopio O, Saia G, Ferretti M, Bedogni G, Chiarini L, Ferronato G, Ninfo V, Lo Russo L, Lo Muzio L, Nocini PF. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2008 Mar:105(3):358-64. doi: 10.1016/j.tripleo.2007.08.040. Epub     [PubMed PMID: 18280968]

[43]

Elad S, Gomori MJ, Ben-Ami N, Friedlander-Barenboim S, Regev E, Lazarovici TS, Yarom N. Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation. Clinical oral investigations. 2010 Feb:14(1):43-50. doi: 10.1007/s00784-009-0311-3. Epub 2009 Jul 15     [PubMed PMID: 19603201]

[44]

Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR. American journal of neuroradiology. 2007 Jun-Jul:28(6):1139-45     [PubMed PMID: 17569974]

Level 2 (mid-level) evidence

[45]

Schulze D, Blessmann M, Pohlenz P, Wagner KW, Heiland M. Diagnostic criteria for the detection of mandibular osteomyelitis using cone-beam computed tomography. Dento maxillo facial radiology. 2006 Jul:35(4):232-5     [PubMed PMID: 16798917]

[46]

Guerrero ME, Jacobs R, Loubele M, Schutyser F, Suetens P, van Steenberghe D. State-of-the-art on cone beam CT imaging for preoperative planning of implant placement. Clinical oral investigations. 2006 Mar:10(1):1-7     [PubMed PMID: 16482455]

Level 2 (mid-level) evidence

[47]

Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dento maxillo facial radiology. 2006 Jul:35(4):236-43     [PubMed PMID: 16798918]

Level 2 (mid-level) evidence

[48]

Krishnan A, Arslanoglu A, Yildirm N, Silbergleit R, Aygun N. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. Journal of computer assisted tomography. 2009 Mar-Apr:33(2):298-304. doi: 10.1097/RCT.0b013e31817e4986. Epub     [PubMed PMID: 19346864]

Level 2 (mid-level) evidence

[49]

Popovic KS, Kocar M. Imaging findings in bisphosphonate-induced osteonecrosis of the jaws. Radiology and oncology. 2010 Dec:44(4):215-9. doi: 10.2478/v10019-010-0032-x. Epub 2010 Jun 24     [PubMed PMID: 22933918]

[50]

Ji X, Pushalkar S, Li Y, Glickman R, Fleisher K, Saxena D. Antibiotic effects on bacterial profile in osteonecrosis of the jaw. Oral diseases. 2012 Jan:18(1):85-95. doi: 10.1111/j.1601-0825.2011.01848.x. Epub 2011 Aug 29     [PubMed PMID: 21883710]

Level 1 (high-level) evidence

[51]

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 May:23(5):1341-1347. doi: 10.1093/annonc/mdr435. Epub 2011 Oct 10     [PubMed PMID: 21986094]

Level 1 (high-level) evidence

[52]

Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Annals of internal medicine. 2006 May 16:144(10):753-61     [PubMed PMID: 16702591]

[53]

Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2004 May:62(5):527-34     [PubMed PMID: 15122554]

Level 2 (mid-level) evidence

[54]

Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. Journal of the American Dental Association (1939). 2005 Dec:136(12):1675-81     [PubMed PMID: 16383049]

[55]

Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK. Teriparatide and osseous regeneration in the oral cavity. The New England journal of medicine. 2010 Dec 16:363(25):2396-405. doi: 10.1056/NEJMoa1005361. Epub 2010 Oct 16     [PubMed PMID: 20950166]

Level 1 (high-level) evidence

[56]

Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2007 Mar:65(3):573-80     [PubMed PMID: 17307613]

Level 3 (low-level) evidence

[57]

Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. The Journal of rheumatology. 2009 Aug:36(8):1835-7. doi: 10.3899/jrheum.081176. Epub     [PubMed PMID: 19671824]

Level 3 (low-level) evidence

[58]

Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. The New England journal of medicine. 2010 Dec 16:363(25):2473-4. doi: 10.1056/NEJMc1002684. Epub 2010 Oct 16     [PubMed PMID: 20950167]

Level 3 (low-level) evidence

[59]

Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, Hemprich A. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2011 Feb:111(2):153-63. doi: 10.1016/j.tripleo.2010.04.015. Epub 2010 Jul 31     [PubMed PMID: 20674411]

[60]

Bedogni A, Saia G, Bettini G, Tronchet A, Totola A, Bedogni G, Ferronato G, Nocini PF, Blandamura S. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral oncology. 2011 May:47(5):420-4. doi: 10.1016/j.oraloncology.2011.02.024. Epub 2011 Mar 24     [PubMed PMID: 21439892]

[61]

Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW, Moon RE, Piantadosi CA. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2012 Jul:70(7):1573-83. doi: 10.1016/j.joms.2012.04.001. Epub     [PubMed PMID: 22698292]

Level 1 (high-level) evidence

[62]

Cella L, Oppici A, Arbasi M, Moretto M, Piepoli M, Vallisa D, Zangrandi A, Di Nunzio C, Cavanna L. Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw. Head & face medicine. 2011 Aug 17:7():16. doi: 10.1186/1746-160X-7-16. Epub 2011 Aug 17     [PubMed PMID: 21849044]

Level 3 (low-level) evidence

[63]

Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M. Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral oncology. 2012 May:48(5):469-74. doi: 10.1016/j.oraloncology.2011.12.004. Epub 2012 Jan 20     [PubMed PMID: 22265335]

Level 3 (low-level) evidence

[64]

Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP, Nammour S. Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers in medical science. 2010 Jan:25(1):101-13. doi: 10.1007/s10103-009-0687-y. Epub 2009 Jun 19     [PubMed PMID: 19543768]

[65]

Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2012 Mar:41(3):214-21. doi: 10.1111/j.1600-0714.2011.01091.x. Epub 2011 Sep 30     [PubMed PMID: 21958312]

[66]

Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. Journal of the American Dental Association (1939). 2007 Jul:138(7):971-7     [PubMed PMID: 17606496]

Level 3 (low-level) evidence

[67]

Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2006 Oct:102(4):433-41     [PubMed PMID: 16997108]

[68]

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Australian endodontic journal : the journal of the Australian Society of Endodontology Inc. 2009 Dec:35(3):119-30. doi: 10.1111/j.1747-4477.2009.00213.x. Epub     [PubMed PMID: 19961450]

[69]

Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2007 Mar:65(3):369-76     [PubMed PMID: 17307580]

[70]

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE, Canadian Association of Oral and Maxillofacial Surgeons. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. The Journal of rheumatology. 2008 Jul:35(7):1391-7     [PubMed PMID: 18528958]

Level 3 (low-level) evidence

[71]

Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H, American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. Journal of the American Dental Association (1939). 2011 Nov:142(11):1243-51     [PubMed PMID: 22041409]